December 24, 2025 — Watertown, MA- Biopharma PEG has expanded its PEGylated protein development platform, offering an integrated set of services that spans recombinant protein expression, PEG conjugation, purification, and analytical characterization. The platform is designed to support biologic drug development from early research through clinical stages, with an emphasis on reproducibility, analytical transparency, and scalable processes.

PEGylation is a widely applied protein modification technology in biopharmaceutical development, involving the covalent attachment of polyethylene glycol (PEG) chains to therapeutic proteins. This approach is commonly used to improve pharmacokinetic profiles, enhance molecular stability, and reduce immunogenicity, making it particularly relevant for biologics advancing into clinical evaluation.

Integrated Protein Expression and Modification Capabilities

Biopharma PEG operates established recombinant protein expression systems using both E. coli and yeast platforms. According to the company, more than 100 proteins have been successfully expressed to date for PEGylation projects and drug research applications. These include commonly studied therapeutic proteins such as granulocyte colony-stimulating factor (G-CSF), human growth hormone (hGH), and interferon α-2a, each produced at reported purities of at least 95% and with defined activity and endotoxin specifications.

This integrated approach allows development programs to begin either with in-house protein expression or with customer-supplied proteins, providing flexibility for projects at different stages of clinical research.

PEGylation Strategies and Conjugation Control

The PEGylation platform supports multiple conjugation sites, including the N-terminus, C-terminus, lysine, cysteine, and other amino acid residues. Available chemistries include aldehyde-based N-terminal PEGylation, NHS-ester conjugation targeting lysine residues, maleimide chemistry for cysteine-specific modification, and customized site-specific strategies tailored to protein structure and functional requirements.

“Effective PEGylation requires precise control over conjugation chemistry and analytical outcomes,” said Dr. Tang, Scientist at Biopharma PEG. “Our objective is to deliver PEGylated proteins with well-defined structures, high purity, and consistent performance that meet the expectations of clinical-stage development.”

Analytical Characterization and Quality Assessment

Analytical characterization is incorporated throughout the PEGylation workflow. Quality control methods include size-exclusion chromatography (SEC-HPLC), reverse-phase HPLC, SDS-PAGE, MALDI-TOF mass spectrometry, peptide mapping, and endotoxin testing. These techniques are used to evaluate purity, molecular weight distribution, conjugation homogeneity, and residual free PEG.

The company reports that recent PEGylated protein projects have demonstrated high purity across multiple analytical methods, consistent molecular weights, low endotoxin levels, and minimal free PEG, supporting their suitability for further preclinical and clinical evaluation.

The platform also provides access to a range of PEG linkers, including linear PEGs (monodispersed and polydispersed), Y-shaped PEGs, and multi-arm PEGs such as 4-arm and 8-arm structures. High-purity, GMP-grade PEG materials are available, with customization options for molecular weight, reactive groups, and linker architecture.

By expanding its end-to-end PEGylated protein development capabilities, Biopharma PEG aims to support clinical research programs requiring reliable and scalable approaches to protein modification as part of modern biologic drug development.

About Biopharma PEG

Biopharma PEG specializes in PEGylation technologies and services for biopharmaceutical development, providing integrated solutions from recombinant protein expression to high-purity PEG conjugation and analytical characterization.

Email: sales@biochempeg.com